Assessment of Residual Congestion in Acute Decompensated Heart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAarhus University Hospital
About this trial
DESIGN:
A prospective, multicenter, observational cohort study including 580 patients admitted for acute decompensated heart failure (ADHF).
Ultrasound assessment of congestion (VExUS and LUS) will be performed serially during admission: within 48 hours of admission, at the time diuretic therapy is switched from intravenous to oral, and on the day of discharge. The discharge assessment will serve as the primary predictor.
Treating physicians will be blinded to all ultrasound findings. Patients will be followed for 90 days by telephone follow-up and chart review for the primary endpoint, with extended chart review at one year for selected secondary endpoints.
AIMS:
To determine whether combined ultrasound assessment of venous (VExUS) and pulmonary congestion (LUS) at discharge predicts heart failure readmission and all-cause mortality in patients hospitalized with ADHF.
HYPOTHESIS:
Abnormal VExUS and/or LUS findings at discharge are associated with a higher risk of heart failure readmission and all-cause mortality after 90 days.
Eligibility criteria
Qualifiers
Adults (≥18 years) admitted with ADHF.
Clinical evidence of congestion during admission, indicated by ≥1 of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiologic/ultrasound evidence of pulmonary congestion.
Treatment with ≥40 mg i.v. furosemide or equivalent dose loop diuretic during admission.
Disqualifiers
Pregnancy
Moribund
Solitary kidney
Inability to provide written consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
580 Participants
are grouped into 1 trial groupSponsors and collaborators
Aarhus University Hospital
Lead sponsor
Zealand University Hospital
Collaborator
Amager Hospital
Collaborator
Source ClinicalTrials.gov